In this month’s Drug Topics, correspondent Kathleen Gannon Longo speaks with Jeremy Schafer about the potentially tremendous impact that value assessments will have on future patient reimbursement decisions. Focusing on Oncology treatment, Schafer describes some of the existing value frameworks in play as well as referencing the work being done by the IVI to employ greater transparency in the development of newer value assessment tools.
Read more here.
